Nitazenes Killed 409 People in 2024. That Number Is Already Out of Date.

In 2020, nitazenes killed 27 people in the United States. Four years later, they killed 409. STAT News reported June 18 that 26 different nitazene compounds have now been detected in the U.S. drug supply — the second highest number globally, after Canada — and that some of those analogs exceed fentanyl’s potency at the mu-opioid receptor.

The 409 figure is already wrong. It is 2024 data. The 2025 numbers will be higher, and we will not see them until 2027.

This is the structural problem with synthetic opioid surveillance in the United States: the forensic laboratory system that counts nitazene deaths in the CDC’s drug overdose database runs on a lag of 12 to 18 months. Nitazenes are added to the drug supply, kill people, and get reported to SUDORS (the State Unintentional Drug Overdose Reporting System) months after those deaths occur. By the time the count of 409 deaths for 2024 was published, the 2025 supply had already evolved.

The DEA has now permanently scheduled multiple nitazene compounds under Schedule I, and new compounds receive initial production quotas of 30 grams each — the minimum necessary to conduct research and forensic analysis. This scheduling action is necessary but not sufficient. Scheduling tells manufacturers what they cannot make. It does not remove the 26 already-circulating compounds from the supply. It does not give emergency rooms better overdose protocols. It does not tell the person using an opioid product that what they have may be a nitazene that is more potent than the fentanyl they were expecting.

Standard naloxone doses reverse nitazene overdoses, but higher doses may be required and response may take longer. The CDC’s provisional data shows the overall opioid overdose decline holding as of early 2026 — but the nitazene trend line runs counter to that. Deaths from synthetic opioids other than fentanyl are rising while fentanyl deaths are declining.

For providers and emergency responders: treat any overdose that doesn’t respond quickly to standard naloxone dosing as a potential nitazene involvement. Administer a second dose. Prepare to assist breathing until the naloxone takes effect. No test strip currently exists that reliably detects the full range of nitazene compounds — the fentanyl test strip that is your current standard of care does not screen for nitazenes.

The people most at risk do not know that the supply contains 26 different compounds some of which are more potent than anything they have encountered before. They are making decisions about what to use and how much to use based on what they know about fentanyl, which is the wrong drug. That gap — between what the supply actually contains and what the person using it knows it contains — is where those 409 deaths happened.

By the time we have 2025 data, the gap will have grown.